| abstract |
The present disclosure provides 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, comprising Their pharmaceutical compositions, methods of making them, and methods of using them, include methods for treating disease states, disorders, and conditions mediated by JAKs, such as inflammatory bowel disease. |